Aardvark Therapeutics (NASDAQ:AARD) Rating Increased to Sell at Wall Street Zen

Wall Street Zen upgraded shares of Aardvark Therapeutics (NASDAQ:AARD) from a strong sell rating to a sell rating in a report released on Saturday.

A number of other equities analysts have also recently issued reports on the stock. Morgan Stanley restated an “underweight” rating and issued a $3.00 price objective (down from $7.00) on shares of Aardvark Therapeutics in a research note on Friday, May 15th. B. Riley Financial lowered their target price on shares of Aardvark Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a research note on Friday, May 15th. BTIG Research lowered shares of Aardvark Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, May 15th. Weiss Ratings upgraded shares of Aardvark Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, July 2nd. Finally, HC Wainwright restated a “neutral” rating and set a $6.00 price target on shares of Aardvark Therapeutics in a research note on Monday, July 20th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $16.30.

Aardvark Therapeutics Trading Up 2.0%

AARD opened at $6.54 on Friday. The stock has a market cap of $143.10 million, a PE ratio of -2.04 and a beta of 3.81. Aardvark Therapeutics has a 1 year low of $3.35 and a 1 year high of $17.94. The stock’s 50 day simple moving average is $5.65 and its 200-day simple moving average is $6.49.

Aardvark Therapeutics (NASDAQ:AARD) last issued its earnings results on Tuesday, August 11th. The company reported ($0.66) EPS for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.21. Equities analysts forecast that Aardvark Therapeutics will post -3.22 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Aardvark Therapeutics

Several large investors have recently made changes to their positions in AARD. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of Aardvark Therapeutics in the second quarter valued at $42,000. China Universal Asset Management Co. Ltd. acquired a new position in Aardvark Therapeutics during the 4th quarter worth about $47,000. Persistent Asset Partners Ltd bought a new stake in Aardvark Therapeutics during the 4th quarter worth about $56,000. New York State Common Retirement Fund bought a new stake in Aardvark Therapeutics during the 2nd quarter worth about $99,000. Finally, MetLife Investment Management LLC bought a new stake in Aardvark Therapeutics during the 4th quarter worth about $102,000.

Aardvark Therapeutics Company Profile

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (ROR?). ROR? plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective ROR? inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.